Template:Isosorbide dinitrate: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate dosage forms and strengths|Dosage Forms and Strengths]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate contraindications|Contraindications]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate contraindications|Contraindications]]
Line 17: Line 15:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate drug interactions|Drug Interactions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate drug interactions|Drug Interactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate use in specific populations|Use in Specific Populations]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate overdosage|Overdosage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate overdosage|Overdosage]]
Line 25: Line 21:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical pharmacology|Clinical Pharmacology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate nonclinical toxicology|Nonclinical Toxicology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical studies|Clinical Studies]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical studies|Clinical Studies]]
|-
|-

Revision as of 14:59, 31 January 2014